Ask AI
ProCE Banner Activity

Optimal Integration of ADCs Into the Care of Patients With HER2-Negative/Ultralow/Low Metastatic Breast Cancer: A Call to Action

Clinical Thought

In this commentary, an expert faculty reflects on key challenges in integrating ADCs for HER2-low, HER2-ultralow, and HER2-negative MBC and discusses strategies to overcomes barriers to the use of agents, including shared decision-making and patient education. 

Released: October 28, 2025

Share

Provided by

Provided by Clinical Care Options, LLC In partnership with Smart Patients, Inc.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Smart Patients, Inc.

ProCE Banner

Disclosure

Primary Author

Laura A. Huppert, MD: consultant/advisor/speaker: AstraZeneca, Pfizer; researcher: Genentech, Gilead, Greenwich LifeSciences, Johnson & Johnson, Mersana, Pfizer; other financial or material support: Daiichi Sankyo, Gilead, Merck.